DBV Technologies SA ADR DBVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DBVT is a good fit for your portfolio.
News
-
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
-
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
-
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
-
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
-
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
-
DBV Tech Gets Requested Feedback from FDA on Comfort Safety Studies
Trading Information
- Previous Close Price
- $0.68
- Day Range
- $0.71–0.71
- 52-Week Range
- $0.65–2.37
- Bid/Ask
- $0.66 / $0.71
- Market Cap
- $137.37 Mil
- Volume/Avg
- 950 / 57,766
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 105
- Website
- http://www.dbvtechnologies.com
Comparables
Valuation
|
Metric
|
DBVT
|
KDNY
|
VKTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.93 | 7.59 | 18.35 |
Price/Sales | — | 482.40 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DBVT
|
KDNY
|
VKTX
|
|---|---|---|---|
Quick Ratio | 4.20 | 5.72 | 18.92 |
Current Ratio | 4.26 | 5.82 | 19.19 |
Interest Coverage | — | — | — |
Quick Ratio
DBVT
KDNY
VKTX
Profitability
|
Metric
|
DBVT
|
KDNY
|
VKTX
|
|---|---|---|---|
Return on Assets (Normalized) | −31.88% | −37.41% | −23.50% |
Return on Equity (Normalized) | −41.49% | −47.73% | −25.01% |
Return on Invested Capital (Normalized) | −42.24% | −43.85% | −30.29% |
Return on Assets
DBVT
KDNY
VKTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hjpbvkcjf | Rgs | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bmnqltqdf | Lbxdwl | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zlxfnsr | Vxghdf | $99.6 Bil | |
MRNA
| Moderna Inc | Nrtytqtqq | Mbybs | $38.8 Bil | |
ARGX
| argenx SE ADR | Mqpcgwwxt | Mkvx | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Nwbkqgwj | Zcr | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lmwrlqlqc | Zvspgz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fhbhrhfcy | Qmxwxh | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zdngrgngb | Krysv | $12.4 Bil | |
INCY
| Incyte Corp | Fptzbkkph | Zvlzv | $11.9 Bil |